Recent Updates
Recently added Catalysts

Firefly Neuroscience, Inc.

AIFFFDA catalysts, PDUFA dates & pipeline intelligence
$0.89
▼ -0.05 · -5.32%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AIFF financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.6252W HIGH $3.15
Volume
66.68 K
Value Traded
60.23 K
Short % Float
3.87%
Days to Cover
5.4
-9.33%Week
-11.47%1 Month
-18.78%3 Month
-46.67%6 Month
-97.46%5 Year
-86.87%All Time

Cash Data

Unlock AIFF cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
13.94 M
EPS (TTM)
-0.50
P/E Ratio
-
Ent. Value
5.92 M
Total Shares
15.75 M
Float Shares
14.30 M
Insiders
9.23%
Institutions
11.00%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every AIFF catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AIFF Catalyst Timeline

Dated clinical, regulatory and corporate events for Firefly Neuroscience, Inc.

Unlock the full AIFF catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AIFF actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all AIFF historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Firefly Neuroscience, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every AIFF program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
BMB-101 neuropsychiatric disordersPhase 12024-10-16positive topline findings from our recently completed Phase 1 study of BMB-101Read MoreFirefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ TechnologyRead More
Scroll for more · summaries link to the source press release
Unlock every AIFF trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AIFF insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
DeCaprio DavidDirector, Officer (President and COO)Acquisition 44,872 77,866 held$0.00 03/10/2026
Unlock the full AIFF insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in AIFF for Q3 2026.
Unlock every fund holding AIFF
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AIFF
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AIFF ownership
Insider and institutional ownership, quarter by quarter.

AIFF Short Interest

Shares sold short, counted twice a month.

3.87%
Short % of Float
of tradable shares sold short
553.6K
Shares Sold Short
-26.3% vs prior count
5.4 High
Days to Cover
trading days of normal volume to buy every short share back
103.4K
Avg Daily Volume
the average used for days to cover
Unlock AIFF short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock AIFF option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AIFF option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AIFF options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AIFF ranks across every disease it competes in

Competitive Position is a premium feature
See how AIFF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AIFF News

AIFF
Nov 17, 2026
AIFFGeneral
▼ -5.3%today

Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans as Commercial Expansion Accelerates

Firefly Neuroscience reported a 373% year-over-year increase in the utilization of its Evoke™ platform for ADHD scans in pediatric patients. This growth reflects expanding clinical adoption and revenue generation. The company is also leveraging a partnership with NeuroSigma to enhance its diagnostic-to-treatment model. Firefly's proprietary dataset now exceeds 200,000 EEG/ERP brain scans.

Read more →
AIFF
Oct 27, 2026
AIFFGeneral
▲ +6.3%on this news

Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform

Firefly Neuroscience announced its Versus platform, which combines a wireless EEG headset with interactive software, enhancing non-invasive brain-computer interface (BCI) applications. The platform has shipped over 3,000 units and generates revenue while supporting Firefly's long-term growth strategy in the BCI and AI sectors. CEO Greg Lipschitz emphasized the potential for personalized training and broader applications.

Read more →
AIFF
Sep 25, 2026
AIFFGeneral
▲ +68.9%on this news

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience and NeuroSigma have partnered to promote the Monarch eTNS® System, the first FDA-cleared non-drug treatment for pediatric ADHD. This collaboration aims to enhance clinician awareness and access to this innovative therapy through Firefly's Evoke™ platform, which offers objective assessments of brain function. The Monarch device is designed for children aged 7 to 12 who are not currently on ADHD medication.

Read more →
AIFF
Sep 17, 2026
AIFFGeneral
▲ +37.6%on this news

Firefly Neuroscience’s Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial’s AI-Native Operating System for Brain Medicine

Firefly Neuroscience has partnered with Radial to integrate its Evoke™ EEG/ERP platform into Radial's AI-native operating system, RadialOS. This collaboration aims to enhance the diagnostic process in brain medicine by providing objective measures of brain function. The integration is expected to improve personalized treatment options and track patient outcomes effectively across Radial's extensive clinic network.

Read more →
AIFF
Aug 5, 2026
AIFFGeneral

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience reported a remarkable 291% increase in clinical assessments at TMS centers using its FDA-cleared Evoke™ platform. This AI-powered EEG/ERP system enhances the understanding of brain activity, enabling clinicians to tailor treatments for conditions like depression and anxiety. The CEO emphasized the importance of individualized treatment decisions based on objective brain data.

Read more →
AIFF
Jul 28, 2026
AIFFFDA Updates
▼ -6.4%on this news

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

Firefly Neuroscience and Next Health have launched a precision cognitive health initiative following an FDA Advisory Committee's recommendation to ease restrictions on certain neuroprotective peptides. This collaboration aims to integrate AI-driven brain biomarker technology with personalized peptide protocols, potentially enhancing cognitive therapies. However, the recommendation is non-binding and further FDA actions are required for implementation.

Read more →
AIFF
Jun 2, 2026
AIFFGeneral

Firefly’s AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD

Firefly Neuroscience has announced the discovery of a novel electrophysiological biomarker for PTSD using its FDA-cleared Evoke System. This breakthrough follows a partnership with the U.S. Department of War, aimed at improving assessments for military personnel suffering from PTSD. The discovery leverages advanced AI technology to analyze EEG data, potentially transforming diagnostic and treatment approaches for PTSD.

Read more →
AIFF
Apr 13, 2026
AIFFGeneral
▲ +6%on this news

With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World’s First Known 200,000+ Standardized EEG/ERP Depository

Firefly Neuroscience has reached a significant milestone by surpassing 200,000 EEG/ERP brain scans, driven by a sequential growth of 5% to 17% over the past four quarters. This achievement supports their goal of creating the first EEG/ERP-based foundation model of the human brain, enhancing capabilities for cognitive biomarker discovery. The company aims to improve diagnostic methods for neurological disorders using advanced AI technologies.

Read more →
AIFF
Mar 26, 2026
AIFFGeneral
▲ +79.8%on this news

Firefly Confirms Public-Private Partnership with the Department of War

Firefly Neuroscience has announced a partnership with the Department of War to utilize its FDA-cleared EEG/ERP technology for assessing and treating PTSD and TBI in U.S. service members. This collaboration aims to fill a gap in military mental health care by providing objective diagnostic tools. The partnership is expected to expand Firefly's presence in the government and defense health sectors.

Read more →
AIFF
Mar 13, 2026
AIFFGeneral
▲ +58%on this news

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Firefly Neuroscience has announced a significant advancement in identifying ADHD subtypes using AI-powered EEG technology. This breakthrough could enhance clinical diagnosis by providing objective biomarkers, potentially leading to more personalized treatment plans. The company aims to build the world's first EEG/ERP brain foundation model, leveraging a vast repository of brain scans to improve outcomes for ADHD patients.

Read more →
AIFF
Mar 4, 2026
AIFFGeneral
▲ +126.3%on this news· ran to +144% by day 3

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Firefly Neuroscience, Inc. has reported significant growth, including a 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes. The company has partnered with 99 commercial users, completing over 10,800 brain scans. Firefly aims to leverage AI and advanced GPU technology to enhance brain health outcomes and develop a foundation model of the human brain.

Read more →
AIFF
Nov 12, 2025
AIFFGeneral
▲ +5.5%on this news

Firefly Neuroscience Reports Third Quarter 2025 Financial Results

Firefly Neuroscience reported third quarter revenue of $388,000, a thirty percent increase from the prior quarter. Total operating expenses fell to $2.8 million, down thirty five percent from the same period last year. The company recorded a net loss of $2.6 million, or $0.20 per share. This loss represents a thirty eight percent improvement compared to the $4.3 million loss in the previous year.

Read more →
AIFF
Sep 5, 2025
AIFFGeneral

Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America

Firefly Neuroscience has partnered with HealingMaps to provide cognitive electrophysiology analytics to over 2,500 clinics across North America. This collaboration aims to enhance treatment outcomes for patients using ketamine, psilocybin, and TMS therapies by utilizing Firefly's FDA-cleared EEG-based analytics platform. The partnership is expected to empower clinics with objective data and new revenue opportunities.

Read more →
AIFF
Aug 26, 2025
AIFFGeneral

Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform

Firefly Neuroscience has launched its new CLEAR Platform, utilizing NVIDIA's L40S GPU to enhance EEG data quality and processing speed. This innovative technology aims to improve brain health outcomes for patients with neurological disorders by enabling more accurate detection of neural biomarkers. The platform represents a significant advancement in clinical insights and supports Firefly's mission in neuroscience.

Read more →
AIFF
Jul 14, 2025
AIFFGeneral
▼ -6%on this news

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

Firefly Neuroscience has entered a collaboration with Heidelberg University Hospital to study the neurophysiological effects of 15q13.3 copy number variants using its FDA-cleared BNA platform. The study will analyze EEG data from 30 subjects and aims to provide insights into cognitive disorders. This partnership underscores Firefly's commitment to advancing precision neuroscience and enhancing diagnostic methods.

Read more →
AIFF
Jun 23, 2025
AIFFGeneral

Firefly Neuroscience to be Added to the Russell Microcap® Index

Firefly Neuroscience, an AI company focused on brain health, will join the Russell Microcap Index effective June 30, 2025. This inclusion marks a significant milestone for the company, reflecting its progress since its Nasdaq listing. CEO Greg Lipschitz highlighted recent achievements, including advancements in cognitive biomarkers and expansion of their technology platform. The membership is expected to enhance visibility among investors.

Read more →
AIFF
Jun 20, 2025
AIFFGeneral
▼ -8.7%on this newsshared move

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

Firefly Neuroscience has made significant advancements in the objective measurement of subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients. Their study demonstrates that combining EEG/ERP and volumetric MRI can achieve up to 87% accuracy in diagnosing these conditions. This approach promises to enhance early detection and intervention, leveraging Firefly's proprietary technology and extensive database.

Read more →
AIFF
May 6, 2025
AIFFGeneral
▼ -9.9%on this news

Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Firefly Neuroscience has announced the acquisition of Evoke Neuroscience, significantly expanding its database, intellectual property portfolio, and commercial footprint. This acquisition is a strategic move to enhance Firefly's proprietary Brain Network Analytics technology, aimed at improving brain health outcomes. The deal is expected to facilitate rapid growth and innovation within the company.

Read more →
AIFF
May 5, 2025
AIFFGeneral

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Firefly Neuroscience has acquired Evoke Neuroscience, enhancing its database and intellectual property portfolio. This acquisition is expected to significantly expand Firefly's capabilities in developing a foundation model of the human brain. The deal reflects a strategic move to leverage technological synergies and improve brain health outcomes for patients with neurological disorders.

Read more →
AIFF
Feb 21, 2025
AIFFGeneral
▲ +8.2%on this news· ran to -26% by day 3

Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

Firefly Neuroscience has successfully exercised warrants, raising $8.8 million to support its initiatives. The funds will be allocated towards the development of its FDA-cleared Brain Network Analytics technology, aimed at improving brain health outcomes. The company expresses gratitude towards shareholders for their confidence, highlighting a robust cash position extending into mid-2026.

Read more →

About Firefly Neuroscience, Inc.

Kenmore, NY 17 employees fireflyneuro.com
Headquarters1100 MILITARY ROAD, KENMORE, NY, 14217
BIOPHARMAWATCH ELITE
Trade the next AIFF catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime